Analysts Issue Forecasts for NTLA FY2026 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Intellia Therapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst R. Bienkowski expects that the company will post earnings of ($3.05) per share for the year. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share.

Several other analysts also recently commented on NTLA. The Goldman Sachs Group reissued a “sell” rating and issued a $9.00 target price on shares of Intellia Therapeutics in a research report on Friday, February 28th. Canaccord Genuity Group decreased their target price on shares of Intellia Therapeutics from $74.00 to $54.00 and set a “buy” rating for the company in a research report on Tuesday, June 3rd. Truist Financial reduced their price objective on shares of Intellia Therapeutics from $90.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th. Wall Street Zen upgraded shares of Intellia Therapeutics to a “sell” rating in a research note on Monday, March 3rd. Finally, JPMorgan Chase & Co. restated a “neutral” rating and issued a $13.00 price objective (down from $45.00) on shares of Intellia Therapeutics in a research note on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $34.95.

Intellia Therapeutics Stock Down 1.2%

NTLA stock opened at $8.37 on Tuesday. The company has a market capitalization of $866.99 million, a price-to-earnings ratio of -1.54 and a beta of 2.14. Intellia Therapeutics has a 12 month low of $5.90 and a 12 month high of $28.18. The firm has a 50 day moving average of $8.01 and a two-hundred day moving average of $9.95.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.26) by $0.16. The business had revenue of $16.63 million during the quarter, compared to the consensus estimate of $11.39 million. The business’s revenue was down 42.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.12) earnings per share.

Institutional Trading of Intellia Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. ARK Investment Management LLC boosted its holdings in Intellia Therapeutics by 3.8% in the 1st quarter. ARK Investment Management LLC now owns 13,011,015 shares of the company’s stock valued at $92,508,000 after purchasing an additional 474,629 shares during the period. Vanguard Group Inc. increased its stake in Intellia Therapeutics by 5.5% during the first quarter. Vanguard Group Inc. now owns 10,752,031 shares of the company’s stock valued at $76,447,000 after acquiring an additional 561,978 shares during the period. Regeneron Pharmaceuticals Inc. bought a new position in Intellia Therapeutics during the fourth quarter valued at about $43,177,000. Geode Capital Management LLC increased its stake in Intellia Therapeutics by 2.0% during the fourth quarter. Geode Capital Management LLC now owns 2,389,240 shares of the company’s stock valued at $27,865,000 after acquiring an additional 45,930 shares during the period. Finally, Two Sigma Advisers LP increased its stake in Intellia Therapeutics by 94.5% during the fourth quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company’s stock valued at $23,300,000 after acquiring an additional 970,700 shares during the period. 88.77% of the stock is owned by institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.